This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.30% per year. These returns cover a period from January 1, 1988 through December 30, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
BMY Q4 Earnings and Sales Beat Estimates, Shares Down on 2025 Outlook
by Zacks Equity Research
BMY beats on both earnings and sales in the fourth quarter of 2024. However, shares are trading down as the guidance for 2025 is below expectations.
ALNYPositive Net Change BMYNegative Net Change PFENegative Net Change BMRNPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe Update
by Zacks Equity Research
AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business impact of the Chinese investigations remains minor.
SNYNegative Net Change AZNPositive Net Change MRKNegative Net Change AMGNNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
Zacks Initiates Coverage of bioAffinity With Neutral Recommendation
by Debanjana Dey
Discover why Zacks rates bioAffinity as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore BIAF's promising growth prospects and financial health amid market challenges.
BIAFPositive Net Change
biotechnology biotechs medical
RZLT Shares Rise 30.8% in 6 Months: What's Driving the Rally?
by Zacks Equity Research
Rezolute rides on robust clinical development activity for lead candidate ersodetug (RZ358) for treating hypoglycemia caused by hyperinsulinism.
BMRNPositive Net Change RZLTNegative Net Change CSTLNegative Net Change HRMYNegative Net Change
biotechs
RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study
by Zacks Equity Research
Ultragenyx announces new safety and efficacy data from its pivotal study of its investigational candidate, UX111, for patients with Sanfilippo syndrome type A.
ALNYPositive Net Change BMRNPositive Net Change RAREPositive Net Change CSTLNegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
GHRS Stock Rallies 55% in a Week: Here's What You Should Know
by Zacks Equity Research
GH Research stock soars 55% in a week after the company meets the primary goal in a mid-stage depression study of its lead candidate, GH001.
ALNYPositive Net Change BMRNPositive Net Change CSTLNegative Net Change GHRSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novartis Rises 5% Since Q4 Earnings: How Should You Play the Stock?
by Zacks Equity Research
NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors already owning the stock can stay invested.
ALNYPositive Net Change NVSNegative Net Change PTCTNegative Net Change
biotechnology biotechs medical pharmaceuticals
VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%
by Zacks Equity Research
Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.
BMRNPositive Net Change VKTXNegative Net Change CSTLNegative Net Change ERASNegative Net Change
biotechs earnings medical pharmaceuticals
5 Promising Price-to-Book Value Stocks to Buy in February
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. GM, USNA, GBX, KT and ENS are some such stocks.
KTPositive Net Change GMPositive Net Change GBXNegative Net Change ENSPositive Net Change USNANegative Net Change
auto-tires-trucks biotechs business-services transportation
The Zacks Analyst Blog Highlights Amgen, CRISPR, Moderna, Sarepta and Vertex
by Zacks Equity Research
Amgen, CRISPR, Moderna, Sarepta and Vertex are included in this Analyst Blog.
AMGNNegative Net Change VRTXNegative Net Change MRNANegative Net Change SRPTNegative Net Change CRSPNegative Net Change
biotechs
Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval
by Zacks Equity Research
REGN and AMGN are in the spotlight this week on fourth-quarter earnings release.
REGNPositive Net Change BIIBNegative Net Change AMGNNegative Net Change AXSMNegative Net Change VRTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock Up
by Zacks Equity Research
Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes and Obesity care products.
ALNYPositive Net Change NVOPositive Net Change LLYPositive Net Change CSTLNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings?
by Kanishka Das
On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza triple) and Journavx (suzetrigine).
VRTXNegative Net Change MRNANegative Net Change CRSPNegative Net Change
biotechs pharmaceuticals
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook
by Zacks Equity Research
GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.
SNYNegative Net Change GSKNegative Net Change JNJNegative Net Change VIRPositive Net Change
biotechs medical pharmaceuticals vaccines
Company News for Feb 5, 2025
by Zacks Equity Research
Companies In The News Are: RACE, REGN, MPLX, WEC.
REGNPositive Net Change WECNegative Net Change MPLXNegative Net Change RACENegative Net Change
auto-tires-trucks biotechs oil-energy utilities
Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend
by Zacks Equity Research
REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition. The company initiates a dividend program,
REGNPositive Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know
by Zacks Equity Research
INCY's fourth-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.
NVSNegative Net Change INCYNegative Net Change EXELPositive Net Change MIRMNegative Net Change
biotechs
Merck Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '25 View
by Zacks Equity Research
MRK posts encouraging Q4 results. However, the decision to temporarily halt shipments of Gardasil vaccines to China has affected its 2025 sales forecast.
AZNPositive Net Change MRKNegative Net Change CSTLNegative Net Change ERASNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFS
by Zacks Equity Research
Pfizer's late-stage BRAF V600E-mutant mCRC study of the Braftovi combo regimen meets its other dual primary endpoint of PFS with statistical significance.
ALNYPositive Net Change PFENegative Net Change LLYPositive Net Change CSTLNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi
by Zacks Equity Research
The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma and Breyanzi for relapsed or refractory follicular lymphoma.
ALNYPositive Net Change BMYNegative Net Change BMRNPositive Net Change EXELPositive Net Change
biotechnology biotechs pharmaceuticals
Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts?
by Zacks Equity Research
Let's look at five pharma and drug companies, MRK PFE, LLY, AMGN and BMY, which are scheduled to release their fourth-quarter 2024 results later this week.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change LLYPositive Net Change AMGNNegative Net Change
biotechs pharmaceuticals
Should Bristol Myers Stock Be in Your Portfolio Pre-Q4 Earnings?
by Ekta Bagri
BMY is looking to turn its business around, banking on the strong uptake of new drugs. The recent spate of positive regulatory updates also bodes well for the stock. We recommend investors to wait for better entry levels.
BMYNegative Net Change PFENegative Net Change TSVTNegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.
NVOPositive Net Change LLYPositive Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug
by Zacks Equity Research
The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of BIIB/Eisai's Leqembi in the EU for early AD.
BIIBNegative Net Change LLYPositive Net Change PRTANegative Net Change CSTLNegative Net Change
biotechnology biotechs medical pharmaceuticals
Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?
by Sundeep Ganoria
Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.
AMGNNegative Net Change VRTXNegative Net Change MRNANegative Net Change SRPTNegative Net Change CRSPNegative Net Change
biotechs earnings medical pharmaceuticals